| Investigator, Principal |
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 280 | Japan, US, RoW | HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 06/25 | 02/26 | | |
| Recruiting | 1 | 12 | Europe, RoW | 131I-IPA, 18F-FET | Telix International Pty Ltd | Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme | 06/25 | 06/25 | | |
NCT05765851: A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 78 | Europe, Canada, US | DS-1103a, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Advanced Solid Tumor, Breast Cancer | 06/26 | 06/26 | | |
NCT06279728: Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients |
|
|
| Available | N/A | | Europe, US | Datopotamab deruxtecan, Dato-DXd, DS-1062a | Daiichi Sankyo, AstraZeneca | Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer | | | | |
NCT04886544: Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring |
|
|
| Completed | N/A | 72 | Europe | YVOIRE Y-Solution 720 | LG Chem | Jaw Volume Deficit | 05/22 | 01/23 | | |
NCT05133973: Feasibility Study of a Transdermal Continuous Glucose Monitoring (CGM) System in Diabetic Patients |
|
|
| Recruiting | N/A | 12 | Europe | FiberSense CGM | EyeSense GmbH | Diabetes | 12/22 | 12/22 | | |
NCT05769751: A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer |
|
|
| Completed | N/A | 865 | RoW | Electronic medical record and hospital information system or other available resources | Daiichi Sankyo, Inc. | HER2-positive Breast Cancer | 07/23 | 07/23 | | |
BIOPATTERN, NCT06259019: Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease |
|
|
| Recruiting | N/A | 300 | Europe | Liquid Biopsy System (LBS), LBS | PlaqueTec Ltd, Royal Papworth Hospital | Coronary Artery Disease | 05/25 | 07/25 | | |
EUROPA T-DXd, NCT05458401: EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan |
|
|
| Completed | N/A | 256 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo | HER2-positive Breast Cancer | 12/23 | 12/23 | | |
NCT06099639: Medical Access Program for Patritumab Deruxtecan |
|
|
| Available | N/A | | US | HER3-DXd, U3-1402 | Daiichi Sankyo | Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer | | | | |
HHiNPWT7DC, NCT05559697: Study Comparing iNPWT Dressing and Devices Affect on Bioburden Levels and Skin Condition After Seven Days |
|
|
| Completed | N/A | 16 | US | Sponsor incisional negative pressure wound therapy device and dressing, Standard of Care incisional negative pressure wound therapy system | DeRoyal Industries, Inc., Lincoln Memorial University | Skin Reaction to Mechanical, Thermal and Radiation Stimuli, Skin Sensitisation | 03/24 | 03/24 | | |
NCT05120895: An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia |
|
|
| Active, not recruiting | N/A | 3300 | RoW | Mevalotin | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Dyslipidemia | 04/25 | 04/25 | | |
NCT05606094: Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia |
|
|
| Completed | N/A | 450 | RoW | | Daiichi Sankyo Co., Ltd. | Gastric Cancer | 11/23 | 11/23 | | |
NCT06210776: A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) |
|
|
| Recruiting | N/A | 800 | RoW | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo | HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer | 03/28 | 03/28 | | |
ACAB, NCT04292405: Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator |
|
|
| Recruiting | N/A | 60 | US | Wearable Cardioverter Defibrillator, AUDICOR AM | Zoll Medical Corporation | Heart Failure | 03/24 | 05/24 | | |
| Recruiting | N/A | 200 | Europe | | Chelsea and Westminster NHS Foundation Trust, ViiV Healthcare | HIV Infections, Gender Identity, Human Immunodeficiency Virus | 04/24 | 10/25 | | |
| Active, not recruiting | N/A | 70 | US | PQ Bypass System | Endologix | Peripheral Artery Diseases | 06/24 | 06/24 | | |
NCT04927052: A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment |
|
|
| Completed | N/A | 136 | Canada | Revanesse Shape + with Lidocaine, Juvederm Voluma with Lidocaine. | Prollenium Medical Technologies Inc. | Volume Deficit in the Mid-face | 08/23 | 08/23 | | |
| Active, not recruiting | N/A | 5000 | RoW | Edoxaban | Daiichi Sankyo, Inc., Daiichi Sankyo (China) Holdings Co., Ltd. | Non-valvular Atrial Fibrillation | 10/24 | 10/24 | | |
NCT05689190: Non-invasive Flow Measurements in Patients With Lower Extremity Arterial Disease (LEAD) |
|
|
| Recruiting | N/A | 30 | Europe | | Philips Clinical & Medical Affairs Global, Leiden University Medical Center | Lower Extremity Arterial Disease | 12/24 | 12/24 | | |
NCT04635111: A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment |
|
|
| Recruiting | N/A | 30 | US | TURALIO™ | Daiichi Sankyo, Inc. | Hepatotoxicity, Tenosynovial Giant Cell Tumor | 06/25 | 03/36 | | |
MILOS, NCT04579367: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia |
|
|
| Recruiting | N/A | 5000 | Europe | Bempedoic acid and/or its fixed-dose combination with ezetimibe | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Hypercholesterolemia, Mixed Dyslipidemia | 09/25 | 09/25 | | |
| Active, not recruiting | N/A | 7 | US | Actual device PFO closure, GORE® CARDIOFORM Septal Occluder, Thienopyridine (clopidogrel or prasugrel), Plavix, Effient, Sham device PFO closure | W.L.Gore & Associates | Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale | 12/25 | 08/26 | | |
SILVERCARE_AF, NCT05804747: A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation |
|
|
| Recruiting | N/A | 1100 | RoW | Edoxaban | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Atrial Fibrillation | 12/25 | 12/25 | | |
NCT05993234: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) |
|
|
| Recruiting | N/A | 257 | Europe | Trastuzumab deruxtecan, T-DXd, ENHERTU® | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | 12/26 | 09/27 | | |
| Recruiting | N/A | 1350 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer | 06/27 | 09/28 | | |
| Shorr, Andrew F |
NCT05354141: Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) |
|
|
| Recruiting | 3 | 970 | US | ExoFlo, Intravenous normal saline | Direct Biologics, LLC | Acute Respiratory Distress Syndrome, ARDS | 03/25 | 08/25 | | |
| Kim, Chul Sik |
RAMOSE, NCT03909334: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 2 | 160 | US | Osimertinib, Tagrisso, Ramucirumab, Cyramza | Xiuning Le, M.D. Anderson Cancer Center, Eli Lilly and Company | Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer | 07/24 | 10/24 | | |
| Recruiting | 2 | 17 | US | MGC018 | Georgetown University, MacroGenics | Extensive-stage Small-cell Lung Cancer | 05/25 | 05/26 | | |
NCT06248515: A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors |
|
|
| Recruiting | 2 | 18 | US | Sacituzumab govitecan-hziy | Georgetown University, Gilead Sciences | Thymoma, Thymic Carcinoma | 04/26 | 12/26 | | |
NCT04499053: Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 18 | US | Durvalumab, Tremelimumab | Georgetown University, AstraZeneca | Carcinoma, Non-Small Cell Lung | 12/24 | 12/24 | | |
NCT05142696: A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab |
|
|
| Recruiting | 1/2 | 200 | Europe, US | [177Lu]Lu-DOTA-TATE, Lutathera, Lutetium (177Lu) oxodotreotide, Lutetium Lu 177 dotatate, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide | Novartis Pharmaceuticals | Extensive Stage Small Cell Lung Cancer | 05/25 | 05/28 | | |
| Recruiting | 1 | 447 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | Tesaro, Inc. | Neoplasms | 04/25 | 04/27 | | |
|
|
|
NCT05274451: A Study to Investigate LYL797 in Adults With Solid Tumors |
|
|
| Recruiting | 1 | 54 | US | LYL797 | Lyell Immunopharma, Inc. | Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC | 03/25 | 09/26 | | |
NCT05786924: A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers |
|
|
| Recruiting | 1 | 100 | US | BDTX-4933 | Black Diamond Therapeutics, Inc. | Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D | 06/26 | 12/26 | | |
| Pishvaian, Michael J |
TIGeR-PaC, NCT03257033: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC |
|
|
| Recruiting | 3 | 320 | Europe, US | Gemcitabine, Gemzar, nab-paclitaxel, Abraxane, RenovoCath, RenovoCath RC120 | RenovoRx | Locally Advanced Pancreatic Cancer | 09/22 | 09/23 | | |
NCT02249949: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery |
|
|
| Completed | 2 | 15 | US | efatutazone | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Daiichi Sankyo, Inc. | Liposarcoma | 10/18 | 05/23 | | |
| Active, not recruiting | 2 | 350 | Europe, Canada, US | 9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar | Actuate Therapeutics Inc. | Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma | 11/24 | 11/25 | | |
NCT03376659: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma |
|
|
| Terminated | 1/2 | 8 | US | Durvalumab, MEDI4736, CV301, Capecitabine, Xeloda, Bevacizumab, Avastin | Georgetown University, Mayo Clinic, Indiana University, Emory University, National Cancer Institute (NCI), George Mason University, Thomas Jefferson University, MedImmune LLC, Bavarian Nordic | Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | 08/21 | 08/23 | | |
|
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 40 | Japan, US | tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA | Seagen Inc. | Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma | 03/25 | 10/25 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) |
|
|
| Recruiting | 1 | 475 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | GlaxoSmithKline | Neoplasms | 08/25 | 02/27 | | |
NCT03209401: Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies |
|
|
| Terminated | 1 | 23 | US | Niraparib, MK-4827, Carboplatin, Paraplatin | Georgetown University, Tesaro, Inc., Oregon Health and Science University | Solid Tumor, Adult, Homologous Recombination Deficiency | 10/23 | 10/23 | | |
| Recruiting | 1 | 120 | Japan, US | EO-3021 | Elevation Oncology | Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms | 09/28 | 12/28 | | |
| Gibney, Geoffrey |
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) |
|
|
| Recruiting | 2 | 267 | US, RoW | mRNA-4157, Pembrolizumab | ModernaTX, Inc., Merck Sharp & Dohme LLC | Melanoma | 09/29 | 09/29 | | |
|
|
NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors |
|
|
| Recruiting | 1 | 108 | US | LYL845 | Lyell Immunopharma, Inc. | Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer | 08/25 | 09/27 | | |
| Conlin, Alison |
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
|
|
| Recruiting | 3 | 1031 | Canada, US | Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc. | Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma | 01/28 | 05/35 | | |
|
| Active, not recruiting | 2 | 70 | US | tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201 | Seagen Inc. | HER2 Positive Breast Cancer | 07/24 | 10/25 | | |
CA209-8H3, NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients |
|
|
| Active, not recruiting | 2 | 30 | US | Nivolumab, Opdivo, Ipilimumab, Yervoy, Bicalutamide, Casodex | Providence Health & Services, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center | Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor | 08/24 | 04/26 | | |
BRIDGET, NCT05323955: Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib |
|
|
| Recruiting | 2 | 48 | US | Trastuzumab, Herceptin, Trastuzumab Emtansine (T-DM1), Pertuzumab, Perjeta, Tucatinib, Tukysa | Carey Anders, M.D., Seagen Inc. | Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer | 10/26 | 10/27 | | |
NCT06353997: Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients |
|
|
| Not yet recruiting | 2 | 12 | US | Pembrolizumab, KEYTRUDA, INBRX-106 | Providence Health & Services, Inhibrx, Inc. | Triple Negative Breast Cancer | 06/26 | 06/29 | | |
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas |
|
|
| Recruiting | 2 | 124 | US | Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation | Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation | 10/24 | 10/24 | | |
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases |
|
|
| Recruiting | 2 | 186 | US | Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849 | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited | CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation | 10/24 | 06/25 | | |
RaPhLRR, NCT05467891: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 200 | US | Ribociclib, Kisqali, Fulvestrant, Faslodex, Anastrozole, Arimidex, Letrozole, Femara, Exemestane, Aromasin | Oana Danciu, Novartis Pharmaceuticals | Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer | 12/24 | 12/27 | | |
2019-101826, NCT04896320: Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. |
|
|
| Withdrawn | 1/2 | 40 | US | Tucatinib | Providence Health & Services, Seagen Inc. | Breast Cancer Stage IV | 06/23 | 06/23 | | |
| Seaward, Samantha A |
| Active, not recruiting | 3 | 354 | US | Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac | SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc. | Colorectal Neoplasms | 02/27 | 02/32 | | |
| Thourani, Vinod |
NCT02732691: JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study |
|
|
| Active, not recruiting | N/A | 68 | Europe, US, RoW | JenaValve Pericardial TAVR System | JenaValve Technology, Inc. | Aortic Valve Stenosis, Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Ventricular Outflow Obstruction | 05/19 | 04/24 | | |
| Terminated | N/A | 12 | US | Edwards Cardioband System, Transcatheter mitral valve repair (TMVr), Guideline Directed Medical Therapy | Edwards Lifesciences | Functional Mitral Regurgitation, Mitral Regurgitation, Mitral Insufficiency | 07/19 | 09/22 | | |
NCT03539458: Feasibility Study of the Tendyne Mitral Valve System in Mitral Annular Calcification |
|
|
| Active, not recruiting | N/A | 11 | US | Tendyne Mitral Valve System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Annular Calcification, Mitral Annulus Calcification, Cardiovascular Diseases, Valve Heart Disease, Heart Valve Diseases, Heart Valve Calcification, Mitral Valve Disease | 11/19 | 10/24 | | |
NCT02732704: THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study |
|
|
| Active, not recruiting | N/A | 100 | Europe, US | JenaValve Pericardial TAVR System | JenaValve Technology, Inc. | Aortic Regurgitation | 08/22 | 09/27 | | |
| Active, not recruiting | N/A | 180 | US | JenaValve Trilogy Heart Valve System | JenaValve Technology, Inc. | Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease | 08/23 | 08/28 | | |
| Active, not recruiting | N/A | 25 | Canada, US | HARPOON™ Beating Heart Mitral Valve Repair System | Edwards Lifesciences | Mitral Regurgitation | 10/23 | 12/27 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
| Recruiting | N/A | 15 | US | Transcatheter Tricuspid Valve Replacement | Trisol Medical | Tricuspid Regurgitation | 01/25 | 07/27 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 06/24 | 06/28 | | |
| Recruiting | N/A | 30 | Canada, US | Cephea Mitral Valve System | Abbott Medical Devices | Mitral Regurgitation | 06/24 | 06/29 | | |
| Recruiting | N/A | 1070 | Europe, US | Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure | 06/24 | 12/29 | | |
NCT05913908: EFS of the DUO System for Tricuspid Regurgitation (TANDEM II) |
|
|
| Recruiting | N/A | 15 | US | DUO Transcatheter Tricuspid Coaptation Valve System, DUO System | CroiValve Limited | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases | 04/25 | 10/29 | | |
| Recruiting | N/A | 870 | Canada, US | Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease | 12/24 | 03/29 | | |
NCT03382457: Clinical Study of Edwards Cardioband Tricuspid Valve Reconstruction System |
|
|
| Active, not recruiting | N/A | 55 | US | Transcatheter Tricuspid Valve Reconstruction, Edwards Cardioband Tricuspid Valve Reconstruction | Edwards Lifesciences | Tricuspid Regurgitation | 01/25 | 01/30 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MitraClip™ device implantation, Mitral Valve Repair Surgery | Abbott Medical Devices | Mitral Valve Regurgitation | 04/26 | 04/34 | | |
| Active, not recruiting | N/A | 500 | Canada, US | MITRIS RESILIA Mitral Valve, Model 11400M | Edwards Lifesciences | Mitral Stenosis, Mitral Valve Insufficiency | 01/28 | 12/35 | | |
| Recruiting | N/A | 6500 | Europe, Canada, US | AtriClip LAA Exclusion System | AtriCure, Inc., Population Health Research Institute | Ischemic Stroke, Systemic Embolism | 12/31 | 04/32 | | |
| Castro, Luis |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 350 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
| Active, not recruiting | 2 | 247 | US | SurVaxM | MimiVax, LLC, Translational Drug Development, Merit | Newly Diagnosed Glioblastoma | 08/24 | 08/24 | | |
| Recruiting | 2 | 78 | US | Pembrolizumab, MK3475, Olaparib, MK-7339, Temozolomide, Temodar | L. Nicolas Gonzalez Castro, MD, PhD, Merck Sharp & Dohme LLC | Glioblastoma, Recurrent Glioblastoma | 12/24 | 12/25 | | |
| Recruiting | N/A | 142 | Europe, US | AtriCure ISOLATOR Synergy Surgical Ablation System | AtriCure, Inc. | Inappropriate Sinus Tachycardia | 06/26 | 06/27 | | |
| Shupp, Jeffrey |
NCT05156983: A Study of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation |
|
|
| Recruiting | 3 | 328 | Europe, Canada, US | TAK-330, SOC 4F-PCC | Takeda, Takeda Development Center Americas, Inc. | Coagulation Disorder | 11/25 | 11/25 | | |
NCT04040660: Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries |
|
|
| Available | N/A | | US | NexoBrid | MediWound Ltd | Thermal Burn | | | | |
NCT05023135: DeepView SnapShot Portable (DV-SSP): Device Training Study |
|
|
| Completed | N/A | 251 | US | DeepView SnapShot Portable (DV-SSP) | SpectralMD | Burns, Wound Heal | 04/23 | 04/23 | | |
| Ulaner, Gary |
MIRROR, NCT06074510: PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer |
|
|
| Recruiting | 4 | 274 | US | Piflufolastat F 18 Intravenous Solution [PYLARIFY], PYLARIFY, 18F-DCFPyL | Lantheus Medical Imaging | Prostate Cancer | 12/24 | 01/26 | | |
ACTION-1, NCT05477576: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy |
|
|
| Active, not recruiting | 3 | 288 | Europe, Canada, US, RoW | RYZ101, Everolimus 10 mg, Sunitinib 37.5 MG, Octreotide LAR 60 MG Injection, Lanreotide 120Mg Sa Susp Inj Syringe | RayzeBio, Inc. | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | 07/25 | 07/28 | | |
AlphaBreak, NCT06402331: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
|
|
| Recruiting | 2/3 | 60 | US | FPI-2265, Ac225-PSMA I&T | Fusion Pharmaceuticals Inc. | Metastatic Castration-resistant Prostate Cancer | 07/26 | 01/31 | | |
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 110 | Canada, US | FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068 | Fusion Pharmaceuticals Inc., AstraZeneca | Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | 12/26 | 12/27 | | |
| Benson, Richard |
| Active, not recruiting | 3 | 785 | Europe | Cisplatin, CDDP, Platinol, Durvalumab, MEDI-4736, Imfinzi, Radiotherapy | University of Birmingham, AstraZeneca, Cancer Trials Ireland | Oropharyngeal Cancer | 12/26 | 12/30 | | |
| Huddleston, Heather |
NCT05394662: Safety and Effectiveness of Juveena™ Hydrogel System Following TCGP At High-Risk for Intrauterine Adhesions |
|
|
| Recruiting | 3 | 150 | US | Juveena Hydrogel System | Rejoni Inc. | Intrauterine Adhesion | 03/25 | 03/25 | | |
| Recruiting | N/A | 56 | US | DEXCOM Continuous Glucose Monitor (CGM) | University of California, San Francisco, DexCom, Inc. | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Dysglycemia, Insulin Resistance | 07/25 | 07/25 | | |
| Bernardo, Nelson |
| Recruiting | N/A | 376 | Europe, US, RoW | SELUTION SLR™ DEB 014, Plain (Uncoated) Balloon Angioplasty (PTA) | MedAlliance, LLC, NAMSA | Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities | 11/24 | 07/28 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
| Recruiting | N/A | 300 | Europe, US, RoW | SELUTION SLR™ 018 DEB, Plain (Uncoated) Balloon Angioplasty (PTA) | MedAlliance, LLC, NAMSA | Peripheral Arterial Disease, Superficial Femoral Artery Stenosis | 12/24 | 12/29 | | |
NCT04543539: IN.PACT™ AV Access Post-Approval Study (PAS002) |
|
|
| Recruiting | N/A | 240 | US | IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort, IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort | Medtronic | Arteriovenous Fistula, Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion, Fistula | 02/25 | 02/29 | | |
| Rizik, David G |
SYNIVUS-DAPT, NCT03606642: SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy |
|
|
| Active, not recruiting | 2 | 50 | US | Dual Antiplatelet (DAPT) Therapy, Ticagrelor (Brilinta), Clopidogrel (Plavix), Prasugrel (Effient) with Aspirin, The Synergy® stent | HonorHealth Research Institute, Boston Scientific Corporation | Coronary Artery Disease, Atherosclerosis, Stent Placement | 12/21 | 12/23 | | |
| Active, not recruiting | N/A | 572 | Europe, Canada, US | TriClipTM Device | Abbott Medical Devices | Tricuspid Regurgitation | 11/22 | 04/29 | | |
| Recruiting | N/A | 120 | Europe, US | PerQseal® Closure Device System | Vivasure Medical Limited | Percutaneous Large Hole Vascular Closure | 05/24 | 08/25 | | |
| Recruiting | N/A | 25 | US | J-Valve TF System | JC Medical, Inc. | Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation | 03/24 | 06/29 | | |
NCT03735667: ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement |
|
|
| Recruiting | N/A | 2820 | Canada, US | ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL | Boston Scientific Corporation | Aortic Stenosis | 06/24 | 11/34 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 06/24 | 06/28 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/24 | 12/28 | | |
DTU-STEMI, NCT03947619: Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial |
|
|
| Recruiting | N/A | 668 | Europe, Canada, US | Impella CP® placement prior to reperfusion with Primary PCI | Abiomed Inc. | ST Elevation (STEMI) Myocardial Infarction of Anterior Wall | 11/24 | 10/30 | | |
| Active, not recruiting | N/A | 102 | Europe, US | XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) | Abbott Medical Devices | Coronary Artery Disease | 08/25 | 08/27 | | |
